501 Canal Boulevard
About Sangamo Therapeutics
Sangamo Therapeutics is focused on translating ground-breaking science into genomic therapies that transform patients' lives using the company's industry leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The Company has open Phase 1/2 clinical trials in Hemophilia A and Hemophilia B, and lysosomal storage disorders MPS I and MPS II. Sangamo has an exclusive, global collaboration and license agreement with Pfizer Inc. for gene therapy programs for Hemophilia A, with Bioverativ Inc. for hemoglobinopathies, including beta thalassemia and sickle cell disease, and with Shire International GmbH to develop therapeutics for Huntington's disease. In addition, it has established strategic partnerships with companies in non-therapeutic applications of its technology, including Sigma-Aldrich Corporation and Dow AgroSciences.
478 articles with Sangamo Therapeutics
Shares of Brisbane, Calif.-based Sangamo Therapeutics plunged 30 percent Thursday after the company released preliminary results from a gene-editing trial that investors saw as less than stellar.
Sangamo Announces Interim Results Of Phase 1/2 CHAMPIONS Study Showing Preliminary Evidence Of In Vivo Genome Editing In Patients With MPS II Treated With SB-913
- Liver biopsy analysis detected targeted integration of IDS transgene, providing preliminary molecular evidence of in vivo genome editing in humans
Sangamo Announces Interim Results Of Phase 1/2 EMPOWERS Study Evaluating SB-318 Zinc Finger Nuclease (ZFN) In Vivo Genome Editing Demonstrating Increased Leukocyte IDUA Activity In Patients With MPS I
Sangamo Therapeutics, Inc. (NASDAQ: SGMO) today presented interim data from the Phase 1/2 EMPOWERS Study evaluating the SB-318 zinc finger nuclease (ZFN) in vivo (inside the body) genome editing product candidate in patients with Mucopolysaccharidosis Type I (MPS I).
Sangamo Therapeutics To Host Conference Call To Review Interim Results From Phase 1/2 CHAMPIONS And EMPOWERS Studies For MPS II And MPS I
Sangamo Therapeutics, Inc. announced that management will host a conference call on February 7th at 12:30 p.m. Eastern Time.
1/25/2019Movers and Shakers is BioSpace's weekly roundup of leadership appointments and changes within the biopharma world. Included this week are Genentech, Editas, Sage, Sangamo, and more.
Sangamo Therapeutics, Inc. announced that Sandy Macrae, CEO of Sangamo, will present a corporate overview at the 37th Annual J.P. Morgan Healthcare Conference on Wednesday, January 9th at 11:30 a.m. PT in San Francisco
Sangamo Therapeutics, Inc. announced that interim clinical data from the Company's inherited metabolic diseases development programs will be presented at WORLDSymposium, an annual conference dedicated to lysosomal diseases being held February 4-8th, 2019 at the Hyatt Regency Orlando in Orlando, Florida
Sangamo Announces Treatment Of First Patient In Phase 1/2 Clinical Trial Of In Vivo Genome Editing Therapy For Hemophilia B
Treatment of the first patient in the Phase 1/2 clinical trial evaluating SB-FIX, an investigational in vivo genome editing therapy for patients with hemophilia B.
Sangamo Therapeutics, Inc. today announced the completion of the acquisition of TxCell, SA. TxCell is now a subsidiary of Sangamo and has been delisted from the French stock market.
Conference Call and Webcast Scheduled for 5:00 p.m. Eastern Time
Sangamo Therapeutics, Inc. announced today that management will participate in the following healthcare investor conferences in November.
Sangamo Therapeutics (Nasdaq: SGMO) announced today that the Company will release its third quarter 2018 financial results after the market closes on Thursday, November 8, 2018.
10/22/2018The U.S. Bureau of Labor Statistics predicts a 7 percent increase in jobs for biomedical engineers and a 13 percent increase in medical scientists.
Allogene Therapeutics began trading on the Nasdaq Stock Exchange today under the ALLO ticker. The price was at the top of its range, $18 per share. The company plans to raise $288 million with the sale of about 16 million shares.
Sangamo and TxCell announce the completion of the acquisition by Sangamo of majority of TxCell ordinary shares
Stéphane Boissel, CEO of TxCell, joins Sangamo as Executive Vice President, Corporate Strategy.
TxCell announces first-half 2018 financial results and update on the proposed acquisition by Sangamo Therapeutics, Inc.
TxCell SA today announces financial results for the first half of 2018 and provides an update on the proposed acquisition by Sangamo Therapeutics, Inc.
Jonathan Drachman, M.D., former CMO of Seattle Genetics, Brings Immuno-Oncology Expertise to Board.
Sangamo Therapeutics Announces Conference Call To Review SB-913 CHAMPIONS Study Data And Participation At Upcoming Investor Conferences
Sangamo Therapeutics, Inc. announced today that management will host a conference call on September 5th at 9:00 a.m. ET to discuss clinical data from the CHAMPIONS Study.
The U.S. Securities and Exchange Commission has leveled charges at a former Sangamo Therapeutics Inc. executive and others for an insider-trading scheme that netted more than $1.5 million in “illegal profits.”
Sangamo Therapeutics, Inc. (NASDAQ: SGMO) announced today that management will present a corporate overview at the 2018 Wedbush PacGrow Healthcare Conference in New York City. The presentation is scheduled for Tuesday, August 14th at 4:15 p.m. ET.